Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
ROCHE PRODUCTS (NEW ZEALAND) LIMITED,Atezolizumab,"Subcutaneous formulation, NSCLC, and all other IV atezolizumab indications",Atezolizumab (Tecentriq),Only if cost neutral or cost saving,Community and Hospital,
